Issn  2249-7579
e Issn  2249-7579
Publisher JOURNAL OF PHARMACEUTICAL BIOLOGY

THE BENEFICIAL THERAPEUTIC AND CARDIOPROTECTIVE EFFECTS OF ATORVASTATIN ON CONGESTIVE HEART FAILURE: AN EXPERIMENTAL AND CLINICAL STUDY

Department of Pharmacognosy and Phytochemistry, Sree Vidyanikethan College of Pharmacy, Tirupathi-517102, Andhra Pradesh, India.
Department of Pharmacognosy and Phytochemistry, Sree Vidyanikethan College of Pharmacy, Tirupathi-517102, Andhra Pradesh, India.
Department of Pharmacognosy and Phytochemistry, Sree Vidyanikethan College of Pharmacy, Tirupathi-517102, Andhra Pradesh, India.
Department of Pharmacognosy and Phytochemistry, Sree Vidyanikethan College of Pharmacy, Tirupathi-517102, Andhra Pradesh, India.
Department of Pharmacognosy and Phytochemistry, Sree Vidyanikethan College of Pharmacy, Tirupathi-517102, Andhra Pradesh, India.
Department of Pharmacognosy and Phytochemistry, Sree Vidyanikethan College of Pharmacy, Tirupathi-517102, Andhra Pradesh, India.

Aimto evaluate potential therapeutic effects of Atorvastatin on experimental heart failure in rats induced by doxorubicin (Dox), and clinically on patients with chronic heart failure. Rats received treatment (for 6 weeks) divided into (n=10 each group); control saline treated rats (1ml, IP), Dox-treated rats (2.5mg/kg, IP) as heart failure group, Atorvastatin-Dox treated rats (10mg/Kg orally), and digoxin-Dox treated rats (0.02mg/kg orally). Clinically, 40 patients with heart failure of EF% <45, divided into 20 control cases, received standard anti-failure treatment only and 20 tested group patients received standard anti-failure treatment plus Atorvastatin (40 mg/day) for 6 weeks. Sera of rats and patients taken for evaluating lipid profiles, high sensitive C-reactive protein (hs-CRP), cardiac troponin-T (cTn-T) and malondialdehyde (MDA). Heart tissues of rats were histologically evaluated. Echocardiographic examination done for both patient groups. Atorvastatin treated rat group showed a significant improvement in signs of heart failure, an increase of systolic blood pressure and body weight, reduced the mortality rate and also, their lipid profiles, cTn-T, hs-CRP, and cardiac MDA levels were significantly reduced in comparison to other groups. Histo logically, less cardiac necrosis and fibrosis with enhancement of neo-vascularisation in cardiac tissues in atorvastatin treated rats. Clinically, patients taken Atorvastatin, had a significant reduction in lipid profiles, cTn-T, hs-CRP, MDA and improvement of heart function parameters (increased of LV-EF and FS%; decreased EDD and ESD) versus controls. Atorvastatin could be a beneficial addition to traditionally anti-heart failure therapy; due to its potential pleiotropic properties independent of their cholesterol-lowering

7 , 1 , 2017

33 - 34